Table.

Effect of different single and combined antithrombotic drugs on thrombotic events and bleeding in patients with cardiovascular disease. The table shows a select group of the different clinical trials. Details of each study are provided in the original references.

Abbreviations. ACS: acute coronary syndrome, ASA: aspirin, CAD: coronary arterial disease, CV: cardiovascular, CVD: cardiovascular disease, DAPT: dual antiplatelet therapy, ICH: Intracerebral hemorrhage, MI: myocardial infarction, PAD: peripheral arterial disease.

Name of Trial	Patient Group	# Patients	Therapeutic Strategy	Efficacy	Safety	Ref
CHARISMA	CVD	15,603	ASA vs ASA+Clopidogrel	No effect on CV death	Similar bleeding	22
TRITON-TIMI 38	ACS with PCI	13608	Prasugrel vs Clopidogrel	Decrease in CV death	Increased bleeding	18
PLATO	ACS with or without ST-elevation	18624	Tricagrelor vs Clopidogrel	Decrease in CV death	Similar bleeding	17
TRILOGY ACS	Unstable angina or MI with or without ST-elevation	7243	Prasugrel vs Clopidogrel	No effect on CV death	Similar bleeding	19
PEGASUS-TIMI 54	MI within 3 yrs	21,162	ASA vs ASA+Ticagrelor	Reduced CV death	Increased bleeding	23
EUCLID	Symptomatic PAD	13885	Tricagrelor vs Clopidogrel	No effect on CV death	Similar bleeding	13
TRA 2P-TIMI 50	History of MI, ischemic stroke or PAD	26,449	ASA vs ASA/DAPT+Vorapaxar	Reduced CV death in patients with stable atherosclerosis	Increased bleeding, ICH	26
TRACER	ACS without ST-elevation	12,944	ASA vs ASA/DAPT+Vorapaxar	No effect on CV death	Increased bleeding, ICH	25
APPRAISE-2	Recent ACS and 2 risk factors	7,392	DAPT vs DAPT+Apixaban	No effect on CV death	Increased bleeding	30
ATLAS ACS 2-TIMI 51	ACS	15,526	DAPT vs DAPT+Rivaroxaban	Reduced CV death*	Increased bleeding	32
COMPASS	Stable atherosclerotic disease, CAD and PAD	27,395	ASA vs ASA+Rivaroxaban	Reduced CV death*	Increased bleeding	35

^*Reduced the composite end point of death from cardiovascular causes, myocardial infarction, or stroke.